Literature DB >> 10928532

Hepatic perfusion before and after the transjugular intrahepatic portosystemic shunt procedure: impact on survival.

E M Walser1, R DeLa Pena, J Villanueva-Meyer, O Ozkan, R Soloway.   

Abstract

PURPOSE: This study correlates transjugular intrahepatic portosystemic shunt (TIPS) mortality with flow patterns in the cirrhotic liver.
MATERIALS AND METHODS: Twenty-seven TIPS patients and 10 control subjects were used for this study. The authors evaluated hepatic perfusion with venous injections of Tc-99m pertechnetate before and after TIPS. Hepatic time-activity curves were analyzed for type and amount of liver perfusion. These parameters were correlated with survival for a mean follow-up of 18 months.
RESULTS: The mean arterial contribution to liver blood flow was 25.4% in the normal control patients, 39.9% in patients prior to TIPS, and increased to 48.3% after TIPS. Although the proportion of arterial supply to the cirrhotic liver varied widely, TIPS mortality did not correlate with the preprocedure hepatic artery/portal venous perfusion ratio. However, patients with both an "arterialized" flow pattern and low total hepatic perfusion had higher mortality, with a mean survival of 2 months compared to patients with a more favorable perfusion profile (mean survival, 28.4 months).
CONCLUSIONS: The proportion of arterial perfusion to the liver before TIPS did not affect survival. However, patients with a combination of reduced total hepatic perfusion and an arterial flow pattern had poorer survival, suggesting that both the quantity and quality of hepatic perfusion predicts TIPS outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928532     DOI: 10.1016/s1051-0443(07)61811-9

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

1.  Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.

Authors:  Renato Ripamonti; Hector Ferral; Marc Alonzo; Nilesh H Patel
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

2.  Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver.

Authors:  Akash Shukla; Pratin Bhatt; Deepak Kumar Gupta; Tejas Modi; Jatin Patel; Milind Phadke; Krantikumar Rathod; Megha Meshram; S J Bhatia
Journal:  Indian J Gastroenterol       Date:  2018-01-24

3.  Hepatic perfusion and hemodynamic effects of transjugular intrahepatic portosystemic shunts.

Authors:  Eric M Walser; Michael Nguyen
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 4.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Construction of Transjugular Intrahepatic Portosystemic Shunt: Bare Metal Stent/Stent-graft Combination versus Single Stent-graft, a Prospective Randomized Controlled Study with Long-term Patency and Clinical Analysis.

Authors:  Chang-Ming Wang; Xuan Li; Jun Fu; Jing-Yuan Luan; Tian-Run Li; Jun Zhao; Guo-Xiang Dong
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

6.  Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).

Authors:  Yue-Meng Wan; Yu-Hua Li; Hua-Mei Wu; Zhi-Yuan Xu; Ying Xu; Li-Hong Yang; Xi-Nan Wu; Jin-Hui Yang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Johannes Chang; Alexia Dumitrache; Nina Böhling; Jasmin Abu-Omar; Carsten Meyer; Deike Strobel; Julian Luetkens; Andreas Minh Luu; Jürgen Rockstroh; Christian P Strassburg; Jonel Trebicka; Maria A Gonzalez-Carmona; Milka Marinova; Michael Praktiknjo
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.